<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01654549</url>
  </required_header>
  <id_info>
    <org_study_id>1391/3/27-573</org_study_id>
    <nct_id>NCT01654549</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis</brief_title>
  <official_title>The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-diabetic Subjects With Non-alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of study was to evaluate the effect of helicobacter pylori eradication on liver fat
      content, liver function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR)
      index, and anthropometric measurements (body mass index and waist circumference)in
      non-diabetic subjects with non-alcoholic fatty liver disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori (HP) antigens have been found in the liver of individuals with benign and
      malignant liver diseases. The role of HP in the pathogenesis of non-alcoholic fatty liver
      disease (NAFLD) is controversial.

      This randomized double blind clinical trial was performed in non-diabetic dyspeptic patients
      with positive antibody to HP and the evidence of fatty liver in ultrasonography. After
      excluding other causes, participants with persistent elevated serum aminotransferase levels
      were presumed to have NAFLD. Those with NAFLD liver fat score greater than (-0.64) and
      positive urea breath test (UBT) were enrolled. They were randomly assigned to lifestyle
      modification alone or lifestyle modification plus HP eradication groups. Quadruple therapy
      (omeprazole, amoxicillin, bismuth subcitrate, and clarithromycin) for HP eradication was
      performed in two weeks. HP eradication was documented by UBT. Liver fat content, fasting
      serum glucose, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase,
      triglyceride, cholesterol, high and low-density lipoprotein, HOMA-IR, and anthropometric
      measurements (body mass index and waist circumference) were checked at baseline and six weeks
      post-treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver Fat Content</measure>
    <time_frame>8 weeks (6 weeks post-treatment)</time_frame>
    <description>Primary outcome measure was changes in the liver fat content from baseline to the end of study (6 weeks post-treatment).
The percent of liver fat was calculated as below:
&quot;Liver fat content (%) = 10 (-0.805 + 0.282 * metabolic syndrome (yes = 1 / no = 0) + 0.078 * type 2 diabetes (yes =2 / no =0) + 0.525 * log fasting serum insulin (mU/L) + 0.521 * log fasting serum AST (U/L) - 0.454 * log (AST/ALT)&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Alanine Aminotransferase Level</measure>
    <time_frame>8 weeks</time_frame>
    <description>Secondary outcome measure was change in serum alanine aminotransferase concentration from baseline to the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Aspartate Aminotransferase Level</measure>
    <time_frame>8 weeks</time_frame>
    <description>Secondary outcome measure was change in serum aspartate aminotransferase concentration from baseline to the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Serum Glucose</measure>
    <time_frame>8 weeks</time_frame>
    <description>Secondary outcome measure was change in fasting serum glucose concentration from baseline to the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Lipid Profile</measure>
    <time_frame>8 weeks</time_frame>
    <description>Secondary outcome measure was change in serum lipid profile (including serum triglyceride, cholesterol, low-density lipoprotein, and high-density lipoprotein concentration) from baseline to the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis Model Assessment-Insulin Resistance (HOMA-IR)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Secondary outcome measure was change in HOMA-IR from baseline to the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric Measurements</measure>
    <time_frame>8 weeks</time_frame>
    <description>Secondary outcome measure was change in anthropometric measurements (body mass index and waist circumference) from baseline to the end of study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Lifestyle modification</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H.pylori eradication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H.pylori eradication</intervention_name>
    <description>Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)</description>
    <arm_group_label>H.pylori eradication</arm_group_label>
    <other_name>H.pylori treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dyspeptic patients with positive antibody to H.pylori and persistent elevated
             aminotransferase levels with the evidence of fatty liver in ultrasonography, who were
             referred to a gastroenterology clinic.

        Exclusion Criteria:

          -  Alcohol use (more than 20 gram per day in men and 10 gram per day in women per day),
             diabetes mellitus, heart disease (ischemic or congestive), hepatic disease (viral
             hepatitis, autoimmune hepatitis, wilson disease, hemochromatosis, liver mass lesion),
             renal disease (serum creatinine concentration of &gt; 1.5 mg/dl), any severe systemic
             co-morbidities, neoplasm, using any medication during the past 3 months, previous
             history of peptic ulcer, previous history of H.pylori eradication, existence of alarm
             signs (weight loss, dysphagia, anemia, vomiting, positive family history of
             gastrointestinal cancers), and pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raika Jamali, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gastroenterology clinic, Sina hospital.</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2012</study_first_submitted>
  <study_first_submitted_qc>July 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <results_first_submitted>October 20, 2012</results_first_submitted>
  <results_first_submitted_qc>November 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 21, 2012</results_first_posted>
  <last_update_submitted>November 21, 2012</last_update_submitted>
  <last_update_submitted_qc>November 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tehran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Raika Jamali</investigator_full_name>
    <investigator_title>Assistant professor of medicine</investigator_title>
  </responsible_party>
  <keyword>Steatohepatitis,</keyword>
  <keyword>Helicobacter pylori,</keyword>
  <keyword>Insulin resistance,</keyword>
  <keyword>Alanine aminotransferase,</keyword>
  <keyword>Aspartate aminotransferase,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lifestyle Modification</title>
          <description>Obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
        </group>
        <group group_id="P2">
          <title>H.Pylori Eradication</title>
          <description>H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>H.pylori eradication not successful</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lifestyle Modification</title>
          <description>Obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
        </group>
        <group group_id="B2">
          <title>H.Pylori Eradication</title>
          <description>H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.90" spread="13.96"/>
                    <measurement group_id="B2" value="41.11" spread="10.14"/>
                    <measurement group_id="B3" value="41.57" spread="12.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Iran, Islamic Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Liver Fat Content</title>
        <description>Primary outcome measure was changes in the liver fat content from baseline to the end of study (6 weeks post-treatment).
The percent of liver fat was calculated as below:
“Liver fat content (%) = 10 (-0.805 + 0.282 * metabolic syndrome (yes = 1 / no = 0) + 0.078 * type 2 diabetes (yes =2 / no =0) + 0.525 * log fasting serum insulin (mU/L) + 0.521 * log fasting serum AST (U/L) – 0.454 * log (AST/ALT)”</description>
        <time_frame>8 weeks (6 weeks post-treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liver Fat Content in H.Pylori Eradication at Baseline</title>
            <description>Liver fat content in Helicobacter pylori eradication plus lifestyle modification group at baseline</description>
          </group>
          <group group_id="O2">
            <title>Liver Fat Content in H.Pylori Eradication at 8 Weeks</title>
            <description>Liver fat content in Helicobacter pylori eradication plus lifestyle modification group at 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Liver Fat Content in Lifestyle Modification at Baseline</title>
            <description>Liver fat content in lifestyle modification group at baseline</description>
          </group>
          <group group_id="O4">
            <title>Liver Fat Content in Lifestyle Modification at 8 Weeks</title>
            <description>Liver fat content in lifestyle modification group at 8 weeks</description>
          </group>
          <group group_id="O5">
            <title>Liver Fat Content Change in H.Pylori Eradication</title>
            <description>The change of liver fat content from baseline to the end of study in H.pylori eradication group</description>
          </group>
          <group group_id="O6">
            <title>Liver Fat Content Change in Lifestyle Modification</title>
            <description>The change of liver fat content from baseline to the end of study in lifestyle modification group</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Fat Content</title>
          <description>Primary outcome measure was changes in the liver fat content from baseline to the end of study (6 weeks post-treatment).
The percent of liver fat was calculated as below:
“Liver fat content (%) = 10 (-0.805 + 0.282 * metabolic syndrome (yes = 1 / no = 0) + 0.078 * type 2 diabetes (yes =2 / no =0) + 0.525 * log fasting serum insulin (mU/L) + 0.521 * log fasting serum AST (U/L) – 0.454 * log (AST/ALT)”</description>
          <units>percentage of liver fat content</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.38" spread="4.47"/>
                    <measurement group_id="O2" value="7.72" spread="4.34"/>
                    <measurement group_id="O3" value="8.50" spread="6.03"/>
                    <measurement group_id="O4" value="7.29" spread="5.06"/>
                    <measurement group_id="O5" value="0.66" spread="0.61"/>
                    <measurement group_id="O6" value="1.21" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Alanine Aminotransferase Level</title>
        <description>Secondary outcome measure was change in serum alanine aminotransferase concentration from baseline to the end of study</description>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Aspartate Aminotransferase Level</title>
        <description>Secondary outcome measure was change in serum aspartate aminotransferase concentration from baseline to the end of study</description>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Serum Glucose</title>
        <description>Secondary outcome measure was change in fasting serum glucose concentration from baseline to the end of study</description>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Lipid Profile</title>
        <description>Secondary outcome measure was change in serum lipid profile (including serum triglyceride, cholesterol, low-density lipoprotein, and high-density lipoprotein concentration) from baseline to the end of study</description>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Homeostasis Model Assessment-Insulin Resistance (HOMA-IR)</title>
        <description>Secondary outcome measure was change in HOMA-IR from baseline to the end of study</description>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anthropometric Measurements</title>
        <description>Secondary outcome measure was change in anthropometric measurements (body mass index and waist circumference) from baseline to the end of study</description>
        <time_frame>8 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>H. Pylori Eradication</title>
          <description>Helicobacter pylori eradication</description>
        </group>
        <group group_id="E2">
          <title>No Intervention</title>
          <description>Lifestyle modification</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations and Caveats</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Raika Jamali</name_or_title>
      <organization>Tehran University of Medical Sciences</organization>
      <phone>982163120000 ext 411</phone>
      <email>jamalira@tums.ac.ir</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

